Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans

1 . A pharmaceutical composition comprising a pharmaceutical compound in solid form having a structure selected from the group consisting of Formulas (III) and (VI), or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient, diluent, or carrier,

wherein in a said pharmaceutical compound having a structure of Formula (III)

Q is a halogen, an alkyl group, a substituted alkyl group, a cyclic alkyl group, an aryl group, a substituted aryl group, a heterocyclic group, an ester, an aldehyde, a ketone, a carboxylic acid, an amide, an amine, an ether, a thiol, a nitrile, or NO2, and R1 is a mono-substitution or a di-substitution with H, a halogen, two halogens, a methyl group, two methyl groups, a butyl group, a substituted alkyl group comprising at least one oxygen, two substituted alkyl groups comprising at least one oxygen, a halogen and an alkyl group, a cyclic alkyl group, an aryl group, a substituted aryl group, a heterocyclic group, an ester, an aldehyde, a ketone, a carboxylic acid, an amide, an amine, an ether, or a nitrile, and

wherein in a said pharmaceutical compound having a structure of Formula (VI)

any of Q1 and Q2 is a halogen, an alkyl group, a substituted alkyl group, methoxy, a cyclic alkyl group, an aryl group, a substituted aryl group, a heterocyclic group, an ester, an aldehyde, a ketone, a carboxylic acid, an amide, an amine, an ether, a thiol or a nitrile and R1 is a mono-substitution or a di-substitution with a halogen, an alkyl group, two alkyl groups, a substituted alkyl group, two substituted alkyl groups, a halogen and an alkyl group, a cyclic alkyl group, an aryl group, a substituted aryl group, a heterocyclic group, an ester, an aldehyde, a ketone, a carboxylic acid, an amide, an amine, an ether, or a nitrile.

2 . The pharmaceutical composition of claim 1 in an oral dosage form.

3 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical compound having a structure of Formula (III) is selected from the group consisting of: a compound wherein Q is F, Cl, or Br, and R1 is 2-F, 3-F, 4-F, 3,5-diF, 3-CI, 4-CI, 3,4-diCI, 4-Br, 3-C1-4-F, 4-Me, 3,4-diMe, 3,5-diMe, 3-MeO, 4-MeO, 3,4-diMeO, 4-t-Bu, 3-C1-4-Me, 3-CH3-4-F, or 3-CN, a compound wherein Q is MeOOCH2 and R1 is selected from H, 2-F, 3-F, 4-F, 3,5-diF, 3-CI, 4-CI, 3,4-diCI, 4-Br, 3-C1-4-F, 4-Me, 3,4-diMe, 3,5-diMe, 3-MeO, 4-MeO, 3,4-diMeO, 4-t-Bu, 3-C1-4-Me, 3-CH3-4-F, and 3-CN, a compound wherein Q is MeO and R1 is selected from H, 2-F, 3-F, 4-F, 3,5-diF, 3-CI, 4-CI, 3,4-diCI, 4-Br, 3-CI-4-F, 4-Me, 3,4-diMe, 3,5-diMe, 3-MeO, 4-MeO, 3,4-diMeO, 4-t-Bu, 3-C1-4-Me, 3-CH3-4-F, and 3-CN, and a compound wherein Q is NO2 and R1 is selected from H, 2-F, 3-F, 4-F, 3,5-diF, 3-CI, 4-CI, 3,4-diCI, 4-Br, 3-C1-4-F, 4-Me, 3,4-diMe, 3,5-diMe, 3-MeO, 4-MeO, 3,4-diMeO, 4-t-Bu, 3-C1-4-Me, 3-CH3-4-F, and 3-CN.

4 . The pharmaceutical composition of claim 3 , wherein the pharmaceutical compound having a structure of Formula (III) is selected from the group consisting of:

Compound C11 wherein Q is MeOOCH2, R1 is H,

Compound C14 wherein Q is MeOOCH2, R1 is 4-F,

Compound C154 wherein Q is Br, R1 is 3,4-diMeO,

Compound C155 wherein Q is Cl, R1 is 3,4-diMeO,

Compound C157 wherein Q is NO2, R1 is 3,4-diMeO,

Compound C195 wherein Q is Cl, R1 is 3-CN, and

Compound C210 wherein Q is NO2, R1 is H.

5 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical compound having a structure of Formula (IV) is selected from the group consisting of a compound wherein any of Q1 and Q2 is F, Cl, Br, or methoxy (OMe), and R1 is OMe, 3,4-di-Me, 4-Cl, 3,4-di-Cl, 4-OMe, 4-Br, 4-t-Bu, 3-Me-4-F, or 4-F.

6 . The pharmaceutical composition of claim 5 , wherein the pharmaceutical compound having a structure of Formula (VI) is selected from the group consisting of:

Compound C289 wherein Q1 is F, Q2 is F, R1 is 4-OMe, and

Compound C290 wherein Q1 is F, Q2 is F, R1 is 4-Br.